Navigation Links
Results From Phase 2 Clinical Study of 6R-BH4 in Peripheral Arterial Disease Not Statistically Significant
Date:2/3/2009

ted the study. Study patients in the treatment group received a total of 400 mg/day of 6R-BH4 twice per day. Approximately 50% of patients in both the placebo and treatment groups were co-administered Vitamin C at 500 mg/day twice daily.

The primary objective of the study was to evaluate mean change in peak walking time from baseline to week 24. The secondary objective of the study was to evaluate the mean change in claudication onset time from baseline to week 24.

About 6R-BH4

6R-BH4, commonly known as BH4 or tetrahydrobiopterin, is a naturally occurring enzyme cofactor that is required for numerous biochemical and physiologic processes, including the synthesis of nitric oxide (NO). NO has been shown to play a key protective role throughout the cardiovascular system and produces multiple positive effects, such as relaxing smooth muscle, reducing blood pressure, controlling inflammation and reducing platelet aggregation. Researchers have demonstrated that a deficiency of BH4 can disrupt NO synthesis, resulting in a loss of normal endothelial NO production. This loss of endothelial NO production, commonly referred to as endothelial dysfunction, has been associated with many cardiovascular diseases, including hypertension, diabetic vascular disease, peripheral arterial disease, coronary arterial disease and pulmonary hypertension, and has been shown to be a strong predictor of cardiovascular adverse events in a number of clinical studies.

About BioMarin BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises three approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme(R) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme(R) (laronidase) for mucopolysaccharidosis I
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Webcast of QIAGEN N.V.s (Nasdaq: QGEN) Fourth Quarter and Year-End 2008 Financial Results Call Set for February 10
2. InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF
3. Corgenix to Host Conference Call to Discuss Second Quarter Results
4. BioMed Realty Trust to Report 2008 Fourth Quarter and Year-End Results
5. BioMS Medical reports results of exploratory phase II trial of dirucotide in relapsing remitting multiple sclerosis
6. Cardica Announces Fiscal 2009 Second Quarter Financial Results
7. ThermoGenesis Corp. to Announce Second Quarter Fiscal 2009 Results on February 4, 2009
8. Repligen Announces Conference Call of Third Quarter Fiscal Year 2009 Results
9. Amicus Therapeutics Announces Fourth Quarter and Year End 2008 Financial Results Release Date
10. CuraGen Reports Fourth Quarter 2008 Financial Results; Provides Milestone and Financial Guidance for First Half of 2009
11. Endo Pharmaceuticals to Announce Fourth Quarter and 2008 Full-Year Financial Results on February 27, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... sophisticated equipment, trained personnel, and detection dogs to ... attacks. A revolutionary new electronic chip with nano-sized ... much easier. , The groundbreaking nanotechnology-inspired sensor, devised ... ,s School of Chemistry and Center for Nanoscience ... Tracense, picks up the scent of explosives molecules ...
(Date:7/24/2014)... prefer to settle into equilibriuma state of unchanging ... realm of non-equilibrium conditions where new possibilities lie. ... phases, such as temperature fluctuations, freezing and melting, ... their body temperature, airplanes to fly, and the ... But even though these conditions exist naturally and ...
(Date:7/24/2014)... , July 24, 2014 SRI International ... with the National Institute of Allergy and Infectious Diseases ... conduct preclinical development of potential therapies for HIV infection ... to treat HIV and AIDS and the complications and ... microbicides for preventing sexual transmission of HIV. ...
(Date:7/24/2014)... 2014  Neogen Corporation (Nasdaq: NEOG ) ... potential revenue from new rodenticide research are premature. In ... on July 22, 2014, Neogen,s CEO commented about several ... "It was my intent Tuesday at our ... a new type of rodenticide, but certainly not to ...
Breaking Biology Technology:Nano-sized chip 'sniffs out' explosives far better than trained dogs 2New approach to form non-equilibrium structures 2National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 2National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 3Neogen comments on SenesTech 2
... 2011 Physicians and scientists from Reproductive Medicine ... results of their groundbreaking research study entitled ... Potential While Blastocyst Biopsy Does Not: A Novel ... Embryos.   The study, led by Richard T. ...
... Intellect Neurosciences, Inc. (OTCPK: ILNS) announces that Dr. Daniel G. ... Annual BIO Investor Forum.  Hosted by the Biotechnology Industry Organization ... and emerging public companies. The meeting will take place October ... Chain will be presenting on October 26th at 1:30 p.m. ...
... Oct. 19, 2011 Process automation specialist Endress+Hauser has ... that develops, produces and distributes sensors, hardware and software ... strengthen its position in the area of biotechnology through ... role in the future, not only in the life ...
Cached Biology Technology:Revolutionary IVF Study May Change the Way Embryos are Biopsied for Genetic Disease 2Revolutionary IVF Study May Change the Way Embryos are Biopsied for Genetic Disease 3Intellect Neurosciences, Inc. to Present at 10TH Annual BIO Investor Forum 2Intellect Neurosciences, Inc. to Present at 10TH Annual BIO Investor Forum 3Endress+Hauser and Finesse Solutions Form Strategic Partnership - Swiss Process Automation Provider Invests in US Biotech Company 2Endress+Hauser and Finesse Solutions Form Strategic Partnership - Swiss Process Automation Provider Invests in US Biotech Company 3
(Date:7/24/2014)... cars ply silent freeways, solar panels blanket rooftops and ... from howling winds and from the blazing desert sun. ... technically and economically feasible to convert California,s all-purpose energy ... in Energy , the plan shows the way ... California that could create tens of thousands of jobs ...
(Date:7/24/2014)... of researchers has developed a new nanoscale agent for ... for assessing the function and properties of the GI ... and treatment of gut diseases. , Illnesses ... and inflammatory bowel disease all occur in the intestine ... with diseases such as diabetes and Parkinson,s. , ...
(Date:7/24/2014)... at NJIT this week for an all-day public forum ... Protection Agency (EPA) to dredge toxic sediment from an ... EPA has called the plan, which proposes removing 4.3 ... of the riverbed, one of the largest cleanups in ... and disposed off-site. , "We need to ensure the ...
Breaking Biology News(10 mins):Stanford study shows how to power California with wind, water and sun 2Stanford study shows how to power California with wind, water and sun 3Stanford study shows how to power California with wind, water and sun 4New imaging agent provides better picture of the gut 2Experts Weigh the Pros and Cons of a $1.7 Billion EPA Cleanup Plan for the Passaic River at an NJIT 2
... COLUMBUS, Ohio Retroviruses such as HIV and HTLV-1 don,t ... their own DNA into the cell,s DNA, and from this ... But that infection might be much less troublesome and much ... response to the virus during its first few days in ...
... major 7.0-magnitude earthquake struck the Haitian capital of Port-au-Prince ... quake was followed by several aftershocks with magnitudes over ... maps suddenly out of date, causing additional challenges to ... can help rescue efforts by providing updated views of ...
... The University of Plymouth is to provide 500,000 funding ... of research in partnership with the University, it was announced ... epidemiology in oral health, including the review of published evidence ... of dental research data. The second will look ...
Cached Biology News:Early immune response needed for hit-and-hide cancer viruses 2First satellite map of Haiti earthquake 2First satellite map of Haiti earthquake 3University of Plymouth invests in dental research 2
... loxP-PGK-gb2-neo-loxP template is designed to allow ... cells. The loxP-PGK-gb2-neo-loxP template encodes ... a prokaryotic promoter (gb2) for expression ... a eukaryotic promoter (PGK) for expression ...
... depletion cocktail is tailored to ... from suspensions of rat spleen ... the StemSep (or compatible 0.5 ... system. The CD4+ T cell ...
Standard Fluka For microscopy (Hist.) redox indicator...
... The VSOS-4 Orbital Shaker is designed ... to provide a uniform motion that is both ... The VSOS-4 Orbital Shaker provides a smooth, quiet, ... for a wide range of laboratory applications such ...
Biology Products: